FDA Grants Fast Track Status to Edgewise’s EDG-5506 for BMD

FDA Grants Fast Track Status to Edgewise’s EDG-5506 for BMD

303052

FDA Grants Fast Track Status to Edgewise’s EDG-5506 for BMD

The U.S. Food and Drug Administration (FDA) has granted fast track status to EDG-5506, Edgewise Therapeutics’ investigational oral therapy for Becker muscular dystrophy (BMD). This designation is given to experimental treatments that are intended to treat serious conditions and fill an unmet medical need. It confers certain benefits, like more frequent meetings with the FDA during the development process, with the aim of expediting the review of much-needed medicines. EDG-5506 was designed to protect muscle cells…

You must be logged in to read/download the full post.